Research Update Mid-year 3 CHF 02428: Identifying the Disease-Defining Autoantibodies in Canine Addison’s Disease

The goal of this project is to identify autoantibodies that are present in the blood of dogs who are newly diagnosed with Addison’s disease in three breeds: Standard Poodles, Portuguese Water Dogs, and English Cocker Spaniels. To accomplish these goals, we have been focusing on (1) collecting blood samples from dogs across all three target breeds, and (2) employing methods that allow us to detect these autoantibodies.

Continue reading “Research Update Mid-year 3 CHF 02428: Identifying the Disease-Defining Autoantibodies in Canine Addison’s Disease”

Research Update Mid-year 3 CHF 02519: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations

We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. An unanticipated complication arose that the mouse monoclonal antibody was no longer being made commercially. B. henselae specific FISH probes have been designed and validation of FISH probes are in-progress. IHC is also in- progress. All qPCR and ddPCR have been completed at this time and samples are waiting for FISH and IHC analysis.

Continue reading “Research Update Mid-year 3 CHF 02519: Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas Within and Between Geographic Locations”

Research Update Mid-year 3 CHF 02488: Addison’s Disease and Symmetrical Lupoid Onychodystrophy in Bearded Collies Provide Common Ground for Identifying Susceptibility Loci Underlying Canine Autoimmune Disorders

Hypoadrenocorticism or Addison’s disease (AD) consists of a life-threatening clinical condition that afflicts multiple purebred and mixed breed dogs. The condition results from autoimmune destruction of the adrenal glands leading to life-long cortisol deficiency. Similarly, another autoimmune condition causing pain and suffering to dogs is Symmetrical Lupoid Onychodystrophy (SLO). For the study of AD and SLO we are investigating the Bearded Collie breed due to the relatively high prevalence of both conditions in this breed and a genomic structure favorable for identifying DNA variations.

Continue reading “Research Update Mid-year 3 CHF 02488: Addison’s Disease and Symmetrical Lupoid Onychodystrophy in Bearded Collies Provide Common Ground for Identifying Susceptibility Loci Underlying Canine Autoimmune Disorders”

Research Update End-year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma

During the first year that the project has been active, we have made progress toward our objectives. The project goals have not been modified.

Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy.

Continue reading “Research Update End-year 1 CHF 02534: Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma”

Research Update Mid-year 2 CHF 02553: Targeted Next Generation Sequencing Panel for Comprehensive Testing of Vector-borne Pathogens

We proposed to develop a comprehensive method for detection of infectious diseases of dogs, taking the guesswork out of determining which tests to use for diagnosis, and potentially improving disease surveillance because of the comprehensive nature of the test.

Continue reading “Research Update Mid-year 2 CHF 02553: Targeted Next Generation Sequencing Panel for Comprehensive Testing of Vector-borne Pathogens”

Research Update End-yr 2 CHF 02528: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases

Diagnostic tests based on the detection of DNA from harmful organisms in clinical samples have revolutionized veterinary medicine in the last decades. Currently, diagnostic panels for several vectorborne diseases (VBDs) are available through universities and private labs in the USA and abroad. However, the vast majority of results from sick dogs are negative, which frustrates veterinarians and dog owners trying to reach a definitive diagnosis.

Continue reading “Research Update End-yr 2 CHF 02528: Developing a Next Generation Sequencing Diagnostic Platform for Tick-Borne Diseases”

Research Update Mid-year 4 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma

Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Recently, advances in the understanding of human lymphomas have focused on the area of epigenetics.

Continue reading “Research Update Mid-year 4 02309-T: Targeting the Cancer Epigenome: The Effect of Specific Histone Lysine Methyltransferase Inhibition in Canine B-Cell Lymphoma”

Research Update End-yr 1 CHF 02651: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling

Canine atopic dermatitis (CAD) is a common allergic skin disease of dogs with a strong genetic basis. Evidence from human studies suggests that several variants of AD exist with different mechanisms and responses to treatment. Current diagnosis of CAD requires time-consuming procedures that involve a considerable cost to the owner. Therefore, new approaches to identify molecular markers that can help with better diagnosis and management of the disease are warranted. In this study, we are using our tailored methodology for lipid biomarker discovery in CAD.

Continue reading “Research Update End-yr 1 CHF 02651: Discovery of Novel Biomarkers of Canine Atopic Dermatitis through Lipid Profiling”

Research Update Mid-year 3 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy

The preparations for the CBD epilepsy study were started in December 2018, including hiring a fulltime research assistant and part-time work/study student, creating all of the study documents necessary for the trial, and creating a newsletter/announcement for Colorado veterinarians. We began enrolling patients for the study at the end of January 2018. We anticipated enrolling 20 patients per year; therefore, we are on track with 54 patients in 2 1/2 years.

Continue reading “Research Update Mid-year 3 CHF 02323: Efficacy of Cannabidiol (CBD) for the Treatment of Canine Epilepsy”